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Proton pump inhibitors are associated with
increased risk of development of chronic
kidney disease
Pradeep Arora1,2* , Anu Gupta1, Mojgan Golzy3, Nilang Patel4, Randolph L. Carter3, Kabir Jalal3 and James W. Lohr1,2
Abstract
Background: Acute interstitial nephritis secondary to proton pump inhibitors (PPIs) frequently goes undiagnosed
due to its subacute clinical presentation, which may later present as chronic kidney disease (CKD). We investigated
the association of PPI use with the development of CKD and death.
Methods: Two separate retrospective case–control study designs were employed with a prospective logistic
regression analysis of data to evaluate the association of development of CKD and death with PPI use. The
population included 99,269 patients who were seen in primary care VISN2 clinics from 4/2001 until 4/2008. For
evaluation of the CKD outcome, 22,807 with preexisting CKD at the first observation in Veterans Affairs Health
Care Upstate New York (VISN2) network data system were excluded. Data obtained included use of PPI (Yes/No),
demographics, laboratory data, pre-PPI comorbidity variables.
Results: A total of 19,311/76,462 patients developed CKD. Of those who developed CKD 24.4 % were on PPI.
Patients receiving PPI were less likely to have vascular disease, COPD, cancer and diabetes. Of the total of 99,269
patients analyzed for mortality outcome, 11,758 died. A prospective logistic analysis of case–control data showed
higher odds for development of CKD (OR 1.10 95 % CI 1.05–1.16) and mortality (OR 1.76, 95 % CI 1.67–1.84) among
patients taking PPIs versus those not on PPIs.
Conclusions: Use of proton pump inhibitors is associated with increased risk of development of CKD and death.
With the large number of patients being treated with proton pump inhibitors, healthcare providers need to be
better educated about the potential side effects of these medications.
Keywords: Chronic kidney disease, Death, Outcomes, Proton pump inhibitors
Background
Proton pump inhibitors (PPIs) became available in the
United States in 1989, and have become one of the most
widely prescribed classes of drugs. The approved indica-
tions for use of PPIs include gastro esophageal reflux
disease (GERD), peptic ulcer disease and erosive esopha-
gitis [1]. However, PPIs are often prescribed outside of
their approved uses. It has been estimated that up to
two-thirds of all people on PPIs do not have a verified
indication for the drug. A 2009 analysis using the
National Ambulatory Medical Care Survey found an
increase in the frequency of prescription PPI treatment
from less than five prescriptions per 1000 GERD-related
physician visits in 1995 to 43.9 prescriptions per 1000
visits in 2006 in the United States, a more than eight-
fold increase [2]. There were a total of 119 million U.S.
prescriptions filled in 2009 for all PPIs totaling $13.6
billion [3].
Several studies have shown increased hazards of
cardiovascular disease and death with PPIs [4–6]. Renal
side effects of PPIs are less often reported and may go
unrecognized. These include acute interstitial nephritis
(AIN), hyponatremia and hypomagnesemia. In general,
most patients with acute kidney injury are assumed to
have acute tubular necrosis. It is not surprising that AIN
secondary to PPI use may also go undetected due to
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several reasons: 1) awareness that PPIs can cause AIN
may not be wide spread; 2) the time interval from drug
initiation to onset of clinical abnormalities is quite vari-
able, ranging from 1 week to 9 months (median 9.9 weeks)
[7]; and 3) typical features of hypersensitivity reaction are
present in only a minority of cases. Patients with undiag-
nosed AKI due to PPIs may present later with chronic
kidney disease (CKD). However, data is lacking on the
association of PPI use with CKD. In this manuscript we
investigate the relationship of PPI use and the develop-
ment of CKD and death.
Methods
Study design and setting
Two separate retrospective case–control study designs
were employed with a prospective logistic regression
analysis of data to evaluate the association of two diffe-
rent outcomes (development of CKD and death) with
PPI use [8]. The data were obtained from the Veterans
Affairs Health Care Upstate New York (VISN2) network,
which is composed of five VA medical centers and 29
community based outpatient clinics. The VISN2 database
contains longitudinal records of 180,553 VA patients,
who were seen in primary care VISN2 clinics from 4/
2001 until 4/2008.
Participants
Patients were included only if they had at least one
outpatient estimated glomerular filtration rate (eGFR)
estimated by the Chronic Kidney Epidemiology (CKD-
EPI) equation during their observation period. For the
CKD study, we excluded patients with an eGFR < 60 ml/
min/1.73 m2 at entry (pre-existing CKD patients). Cases
were identified as those patients who were subsequently
diagnosed with CKD (ie, had an observed eGFR < 60).
Controls were identified as those patients who were not
diagnosed with CKD during their observation period.
Records were retrospectively reviewed starting from the
time of CKD diagnosis for cases, and from the time of
last observation for controls to assess whether or not
risk factors existed in the history of each patient. For the
mortality study, cases were identified as individuals who
died during the observation period and controls as indi-
viduals who were alive on March 31, 2008.
Risk factor variables
The primary risk factor to be tested for significance was
the prescription of proton pump inhibitor (PPI) in the
history of cases or controls. PPI use was determined by
whether a prescription was filled during a quarter. In
addition to use of PPI (Yes/No), the following control
variables were included in the analyses: age, gender, race,
time at risk (ie, time from initial observation in the data
system to the case–control outcome), and the pre-PPI
comorbidity variables: vascular disease, gastrointestinal
(GI) comorbidities, chronic obstructive pulmonary disease
(COPD), cancer, diabetes, and hypertension.
Statistical methods
Descriptive baseline statistics were produced for the study
population. Patients were divided in 2 groups based on
PPI use, Group 1 -on PPI, Group 2 –not on PPI. These
two groups were compared using Fisher exact test for
categorical variables and t-tests for continuous variables.
Similarly descriptive baseline statistics were produced for
patients who developed CKD versus those who did not
and between patients who died versus those who did not.
A prospective logistic analysis of case–control data was
used to investigate the association of treatment (exposure
to PPI) with each outcome of interest [8]; onset of CKD
and mortality, respectively, controlling for age, sex, race,
GI and pre-PPI comorbidities. It was shown by Prentice
and Pyke that the odds ratio estimators and associated
confidence intervals for the effects of risk factor on an
outcome variable in case–control studies may be esti-
mated by applying the standard logistic regression mode-
ling to the case–control data as if the data had been
obtained in a prospective study. Their work generalizes
the findings of Breslow & Powers [9, 10] on the equiva-
lence of odds ratio estimators when both prospective and
retrospective logistic models are applied to case–control
data. We also performed adjusted stratified analysis by
levels of dichotomized versions of the variables in the
initial main-effects model, to test for PPI effects within
subgroups.
Sensitivity analysis
We did several sensitivity analyses: 1. We removed indi-
viduals with baseline CKD for the analysis of mortality
and added CKD (Yes/No) as a covariate in the analysis of
mortality outcome; 2. For the second sensitivity analysis,
we first defined the propensity score as the estimated
probability of receiving PPI, which was obtained from a
logistic regression analysis of PPI on age, race, sex and the
pre-PPI comorbidity variables: vascular disease, COPD,
cancer, diabetes, and hypertension. We repeated our
analysis of case–control data for each outcome of interest
controlling for propensity score instead of controlling for
comorbidities prior to PPI; 3. We also used propensity
score matching (PSM) technique to reduce the bias due to
confounding variables.
It should be noted, in the sensitivity analyses that
involved propensity scoring, all potentially confounding
variables except GI were included in the propensity
score. GI was of particular interest separately and, there-
fore, was added to the model directly as a covariate. This
allows interpretation of the coefficient on PPI as the
effect of PPI unconfounded by preceding GI and the
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coefficient on GI as the effect of preceding GI that is not
mediated through the effect of GI on the decision to
prescribe PPI. Thus, since GI is an indication for PPI
prescription and it is known that GI is associated with
CKD and death, including GI as a covariate directly allows
us to assess whether the effect of GI is mediated through
its effect on PPI.
All of the analyses were performed using SAS 9.2 (SAS
Institute, Cary, NC) [Statistical significance was set to α =
0.05]. The Logistic procedure in SAS was used for the
analysis of each model.
Results
Patient characteristics
After exclusion of patients with no outpatient eGFR
measurement, our sample size was 99,269 individuals.
Of these, 36,282 were on PPI at some time during their
observation period. 22,807 had CKD at the time of first
observation in the VISN2 data system, leaving 76,462
patients for analysis of the CKD onset outcome.
A total of 22,734 were taking PPI (4711 in the case
group and 18023 in the control group). Mean age of the
patients in the data set for analysis of CKD was 56.6 years.
There were 4682 (6.1 %) females and 7719 (10.1 %)
African Americans (AA). Table 1 gives the frequencies of
risk factors for CKD outcome by PPI status. Patients using
PPI were less likely to have vascular disease (15.5 % vs
18.5 %), cancer (7.3 % vs 10.3 %), and diabetes (17.5 % vs
21.2 %) prior to PPI use; and more likely to have COPD
(9.85 % vs 8.92 %) or hypertension (62.5 % vs 62.3 %).
Logistic regression analysis revealed patients with vascular
disease, diabetes, and cancers at baseline were less likely
to have received PPI.
Out of the 99,269 patients in the mortality study,
36,282 were taking PPI at some time during their obser-
vation period. Table 2 gives the frequencies of risk
factors in the mortality outcome study by PPI status. In
the data set for analysis of mortality, mean age of the
patients was 60.6 years. There were 5437 (5.5 %) female
and 8921 (9.0 %) African Americans.
Multivariate analysis
Logistic analyses revealed a statistically significant increase
in the rate of occurrence of mortality and CKD among
patients who were taking PPIs compared to those who
were not taking PPIs (Table 3). Figures 1 and 2 give the
estimated probabilities of event by age for CKD and
mortality analysis. We estimated probability of event by
Table 1 Number and frequencies of risk factors for CKD outcome prior to CKD or end of study time (total of 53,728 individuals not
on PPI and total of 22,734 individuals on PPI)
Not on PPI On PPI p_value
Total Case(CKD) Control Total Case(CKD) Control
53728 14600 39128 22734 4711 18023
Vascular disease (n) 9948 3703 6245 3525 1046 2479 <0.0001
18.52 % 25.36 % 15.96 % 15.51 % 22.20 % 13.75 %
COPD (n) 4792 1541 3251 2239 569 1670 <0.0001
8.92 % 10.55 % 8.31 % 9.85 % 12.08 % 9.27 %
Cancer (n) 5540 1689 3851 1648 443 1205 <0.0001
10.31 % 11.57 % 9.84 % 7.25 % 9.40 % 6.69 %
Diabetes (n) 11410 4515 6895 3976 1206 2770 <0.0001
21.24 % 30.92 % 17.62 % 17.49 % 25.60 % 15.37 %
Hypertension (n) 33496 12024 21472 14202 3734 10468 <0.0001
62.34 % 82.36 % 54.88 % 62.47 % 79.26 % 58.08 %
GI (n) 7494 1913 5581 12832 2324 10508 <0.0001
13.95 13.1 14.26 56.44 49.33 58.3
Black (n) 5404 1067 4337 2315 357 1958 0.5994
10.06 % 7.31 % 11.08 % 10.18 % 7.58 % 10.86 %
Female (n) 3340 534 2806 1342 214 1128 0.099
6.22 % 3.66 % 7.17 % 5.90 % 4.54 % 6.25 %
Age in years (mean) 56.94 66.9 53.2 56.3 63.88 54.32 <0.0001
(STD) 15.38 11 15.2 13.17 10.9 13
Time at risk (quarters) (mean) 10.37 6.55 11.8 14.1 10.83 14.95 <0.0001
(STD) 7.66 5.9 7.74 7.1 6.17 7.08
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Table 2 Frequencies of risk factors for mortality outcome prior to end of study time (total of 62,987 individuals not on PPI and total
of 36,282 individuals on PPI)
Not on PPI On PPI p_value
Total Case (death) Control Total Case (death) Control
62987 6897 56090 36282 4861 31421
Vascular disease (n) 16806 3257 13549 8683 1982 6701 <0.0001
26.68 % 47.22 % 24.16 % 23.93 % 40.77 % 21.33 %
COPD (n) 6856 1696 5160 4298 1116 3182 <0.0001
10.88 % 24.59 % 9.20 % 11.85 % 22.96 % 10.13 %
Cancer (n) 9220 1954 7266 3749 1073 2676 <0.0001
14.64 % 28.33 % 12.95 % 10.33 % 22.07 % 9.52 %
Diabetes (n) 15526 2295 13231 8633 1642 6991 <0.0001
24.65 % 33.28 % 23.59 % 23.79 % 33.78 % 22.25 %
Hypertension (n) 42625 5756 36869 26503 4231 22272 <0.0001
67.67 % 83.46 % 65.73 % 73.05 % 87.04 % 70.88 %
GI (n) 9274 1263 8011 20141 2227 17914 <0.0001
14.72 % 18.31 % 14.28 % 55.51 % 45.81 % 57.01 %
Black (n) 5768 489 5279 3153 362 2791 0.0132
9.16 % 7.09 % 9.41 % 8.69 % 7.45 % 8.88 %
Female (n) 3582 122 3460 1855 109 1746 <0.0001
5.69 % 1.77 % 6.17 % 5.11 % 2.24 % 5.56 %
Age in years(mean) 59.9 72.87 58.34 61.7 70.28 60.37 <0.0001
(STD) 16.12 11.2 15.9 14.1 11.55 14
Time at risk (quarters) (mean) 14.13 11.13 14.5 17.3 14.5 17.72 <0.0001
(STD) 7.63 6.11 7.7 6.64 5.8 6.65
Note: Given p-values are for PPI group differences. For categorical variables, the proportions of patients with the characteristics in two PPI groups were compared
using Fisher exact test. We performed a simple t test analysis, with adjustment for unequal variances when appropriate, to compare the means of
continuous variables
Table 3 Estimate of odds ratios, with the 95 % confidence limits
For Mortality outcome Odds Ratio Estimates For CKD outcome Odds Ratio Estimates
Effect Contract Point Estimate 95 % Wald
Confidence Limits
p-value Point Estimate 95 % Wald
Confidence Limits
p-value
PPI Yes vs No 1.76 1.68 1.84 <.0001 1.10 1.05 1.16 <.0001
age 1 year increase 1.07 1.06 1.07 <.0001 1.07 1.07 1.07 <.0001
Race Black vs White 1.41 1.30 1.53 <.0001 0.92 0.86 0.99 0.0269
Sex Female vs Male 0.62 0.54 0.72 <.0001 1.32 1.20 1.45 <.0001
Vascular Disease Yes vs No 1.52 1.45 1.59 <.0001 0.94 0.89 0.98 0.009
COPD Yes vs No 2.41 2.28 2.54 <.0001 0.97 0.91 1.04 0.378
Cancer Yes vs No 1.91 1.82 2.02 <.0001 0.78 0.74 0.84 <.0001
Diabetes Yes vs No 1.53 1.46 1.61 <.0001 1.66 1.59 1.74 <.0001
Hypertension Yes vs No 1.38 1.30 1.47 <.0001 2.43 2.31 2.55 <.0001
GI Yes vs No 1.03 0.98 1.08 0.25 0.99 0.94 1.04 0.6208
Time at risk 1 quarter increase 0.91 0.91 0.91 <.0001 0.90 0.89 0.90 <.0001
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age from the fitted model (mean time at risk were 12.4
quarters and 15.9 for CKD and mortality, respectively).
There was a significant effect of the interaction of age and
PPI use (p-value <0.0001), in models for both development
of CKD and mortality. The result shows patients younger
than 53 years old were significantly at higher risk of CKD
incidence if taking PPI. Patients younger than 78 years old
had significantly in higher risk of death if taking PPI. To
determine whether the effect of PPI varied according to
baseline characteristics, we performed stratified analyses
for the risk of CKD and mortality. Patients who were
white, male, <65 years and did not have DM, vascular
disease, cancer were at greater risk of CKD outcome if on
PPI than if not on PPI blockers. However mortality out-
come with PPI did not vary based on demographic or
comorbidity (Table 4).
Fig. 1 Estimated probability of CKD by age from the fitted model when interaction of PPI and Age is added to the model for CKD outcome
Fig. 2 Estimated probability of death by age, from the fitted model when interaction of PPI and Age is added to the model for mortality
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Sensitivity analyses
1 Adding CKD (Yes/No) as a covariate in the analysis of
mortality, the CKD effect was significant but the PPI effect
on mortality did not change; 2. When we controlled for
propensity score the odds ratio for CKD outcome was
1.08 (95 % CI 1.03–1.13), and for mortality outcome the
odds ratio was 1.70 (95 % CI 1.62–1.79), for PPI versus no
PPI. 3. For the propensity matched data results were
similar.
Discussion
Our study revealed that PPI use was associated with in-
creased odds of development of CKD and death. Although
the association of PPI use with mortality has been widely
reported, we found an association of PPI use with devel-
opment of CKD. It is not surprising that PPI use is associ-
ated with CKD as these drugs are one of the most
common causes of AIN in the United States [11].
Our study showed that PPI use increased the odds of
development of CKD by 10 %. The most likely explanation
is unrecognized or partially recovered AIN. Thirty to 70 %
of patients with drug induced AIN do not fully recover
their baseline renal function, likely due to rapid transfor-
mation of interstitial cellular infiltrates into large areas of
fibrosis [12]. Simpson et al found an incidence of AIN of
8.0 per 100,000 person-years (95 % CI 2.6–18.7), based on
15 cases and an estimated 750,000 1-month treatments
dispensed annually [13]. Blank et al found similar results
in a case control study [14]. Recovery from AKI occurs
following withdrawal of the offending drug with or with-
out corticosteroid treatment may not be complete and
many patients are left with some degree of renal impair-
ment [11]. Geevasinga et al identified 18 cases of biopsy-
proven PPI-induced AIN causing AKI in a retrospective
case review. All patients recovered renal function, but the
mean calculated creatinine clearance was 15.9 ml/min/
1.73 m2 and 11.5 ml/min/1.73 m2 lower than baseline at 3
and 6 months, respectively [15]. Simpson et al also noted
an incomplete recovery of renal function after PPI induced
AIN [13].
Failure to recognize this entity early in the course may
lead to irreversible interstitial fibrosis and CKD. Thus an
early diagnosis and withdrawal of the offending drug is
the key to prevent potentially life threatening renal fail-
ure. However, this may be difficult because most of these
patients have nonspecific symptoms on presentation. In
a systematic review by Sierra et al including 60 cases of
PPI use associated AIN, 12–30 % patients had nonspe-
cific symptoms and 8 % of patients were asymptomatic.
Pyuria was present in 61 % and eosinophiluria in only
21 % of cases [16]. Only about 10 % of patients with PPI
induced AIN presented with the classic triad of fever,
rash and eosinophilia [11]. Most of these patients had
insidious onset of AKI [13].
Similar results were shown recently by Xie et al [17]
and Lazarus et al [18]. Lazarus et al studied in 2 data
cohort (Atherosclerosis Risk in Communities (ARIC) and
Geisinger Health system replication cohort) and found
that PPI were associated with higher odds for CKD. In the
ARIC cohort use of PPI was defined by self-reported use
and CKD was defined using ICD codes, which had a
specificity of 35.5 %. In the Geisinger Health system repli-
cation cohort, the diagnosis of CKD was based on eGFR
and use of PPI was based on prescription. Both these
cohorts had higher cardiovascular comorbidities in PPI
users (in our cohort PPI users had less cardiovascular
comorbidity) [18]. Higher odds of CKD (1.3–1.5) com-
pared to our cohort (1.10) may be explained by higher
comorbidity and longer duration of follow up in these
cohorts.
In our study we found that younger individuals were
more likely to develop CKD associated with PPI use.
This is in contrast to the observation in Sierra’s system-
atic review of AIN who found that AIN due to PPI was
more common among older patients. Although older
patients are more likely to have multiple comorbidities
and the renal interstitium may be more vulnerable to
damage due to compromised blood flow, allowing a
larger exposure time to the medications [13], PPI use was
associated with increased odds of CKD among younger
patients in our study. It is difficult to speculate the mech-
anism among younger patients. It is possible that the
prevalence of CKD among elderly is high with or without
Table 4 Adjusted OD and 95 % confidence interval for CKD
and Mortality outcomes associated with PPI for each subgroups
Subgroup OR CKD Mortality 95%CI
95%CI OR
Age <65 1.24 1.17 1.29 2.26 2.07 2.47
>65 1.21 0.89 1.69 1.60 1.51 1.70
Gender Female 1.09 0.94 1.49 1.67 1.24 2.30
Male 1.10 1.05 1.15 1.70 1.68 1.85
Race Black 1.01 0.85 1.18 1.68 1.41 2.00
White 1.16 1.06 1.17 1.77 1.68 1.86
GI Absent 1.21 1.14 1.29 2.18 2.00 2.24
Present 0.93 0.86 1.10 1.18 1.08 1.28
DM Absent 1.11 1.05 1.17 1.70 1.60 1.80
Present 1.07 0.99 1.18 1.89 1.74 2.06
HTN Absent 1.21 1.09 1.34 1.63 1.44 1.85
Present 1.07 1.01 1.12 1.78 1.69 1.87
Vascular Absent 1.13 1.07 1.19 1.87 1.76 1.99
Present 1.02 0.93 1.13 1.63 1.51 1.75
Cancer Absent 1.10 1.05 1.16 1.70 1.61 1.80
Present 1.11 0.96 1.28 1.90 1.72 2.11
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PPI, but in the younger population the prevalence of CKD
without PPI use is quite low making the prevalence of
CKD associated with PPI use more significant. In a similar
phenomenon prevalence of cardiovascular comorbidity in
dialysis patients is more than 100 times higher in a youn-
ger population compared to only 2 times higher at the age
of 80 years as compared to the general population [19].
Another potential mechanism by which these medications
can lead to CKD is through progressive chronic interstitial
nephritis due to magnesium deficiency. Hypomagnesemia
has been shown to cause endothelial cell dysfunction,
inflammation and oxidative stress [20, 21]. Also, there is
evidence of association between hypomagnesemia and
albuminuria in patients with type 2 diabetes [22]. Pham et
al reported that serum magnesium level was significantly
associated with the slope of inverse serum creatinine in
type 2 diabetic patients with near normal renal function
[23]. Sakaguchi et al, in a retrospective cohort study found
that hypomagnesemia was significantly associated with
progression to end stage renal disease (ESRD) in patients
with type 2 diabetic nephropathy but not in those with
nondiabetic CKD [24]. Rats fed a magnesium deficient
diet have been shown to have higher urine N-acetyl-β-D-
glucosaminidase levels, reflecting that magnesium defi-
ciency induces renal interstitial tubular injury [25]. We
did not examine the magnesium levels of these patients,
thus additional studies are needed to explore any substan-
tial association between PPI induced hypomagnesemia
and chronic kidney disease. The precise pathogenesis of
chronic kidney disease in patients on proton pump inhibi-
tors needs to be further investigated.
Our study showed that the use of PPIs is associated with
a 75 % increased risk of mortality. Other studies have also
shown a similar association of PPI use and increased risk
of death, especially in elderly and institutionalized patients
and among patients who were on clopidogrel [4, 6].
There are a few limitations to this study. There is poten-
tial for indication bias in our results. However, indication
bias in this cohort is unlikely. In fact, the study patients
on PPI were less likely to have a higher comorbidity
burden than those who did not receive PPI. This actually
strengthens the case for the association of PPI use with
CKD and mortality. Covariates that are not associated
with either treatment or outcome do not cause a bias. The
covariates that are associated with both treatment and
outcome were included in the model and, hence, were
controlled for. It is possible that variables not in our data
set, such as use of NSAIDs, smoking and therefore not
controlled for could cause indication bias, as is true in all
observational studies. Furthermore we also did propensity
score analyses to mitigate indication bias, and the results
didn’t change. However, we note the potential for indica-
tion bias as a limitation of any observational study. We
used one eGFR less than 60 ml/min/1.73 m2 as the
definition of CKD, because although this does not meet
the KDOQI definition, most large epidemiologic studies
have used a single eGFR definition for CKD. Our results
may not be generalizable due to the fact that females and
non-whites are underrepresented in the VA study popula-
tion. However, this was a real world cohort from the
largest integrated health care system in United States and
utilizes a uniform data collection system.
Conclusions
In this study, we found that long-term use of proton
pump inhibitors is associated with increased risk of
development of CKD and death. Although cause and
effect cannot be determined with an observational study,
with the large number of patients being treated with
proton pump inhibitors, healthcare providers need to be
cautious in prescribing these drugs because of the poten-
tial side effects.
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